PL2392326T3 - Składnik sylibininowy do leczenia zapalenia wątroby - Google Patents
Składnik sylibininowy do leczenia zapalenia wątrobyInfo
- Publication number
- PL2392326T3 PL2392326T3 PL11005445T PL11005445T PL2392326T3 PL 2392326 T3 PL2392326 T3 PL 2392326T3 PL 11005445 T PL11005445 T PL 11005445T PL 11005445 T PL11005445 T PL 11005445T PL 2392326 T3 PL2392326 T3 PL 2392326T3
- Authority
- PL
- Poland
- Prior art keywords
- hepatitis
- treatment
- silibinin component
- silibinin
- component
- Prior art date
Links
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title abstract 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title abstract 2
- 229950000628 silibinin Drugs 0.000 title abstract 2
- 235000014899 silybin Nutrition 0.000 title abstract 2
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 208000005176 Hepatitis C Diseases 0.000 abstract 1
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 229960000329 ribavirin Drugs 0.000 abstract 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98816807P | 2007-11-15 | 2007-11-15 | |
| EP07022187 | 2007-11-15 | ||
| EP08005459 | 2008-03-25 | ||
| EP08849759A EP2219642B1 (en) | 2007-11-15 | 2008-11-14 | Silibinin component for the treatment of hepatitis |
| EP11005445.9A EP2392326B9 (en) | 2007-11-15 | 2008-11-14 | Silibinin component for the treatment of hepatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2392326T3 true PL2392326T3 (pl) | 2018-07-31 |
Family
ID=40259958
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08849759T PL2219642T3 (pl) | 2007-11-15 | 2008-11-14 | Komponent sylibininy do leczenia zapalenia wątroby |
| PL11005445T PL2392326T3 (pl) | 2007-11-15 | 2008-11-14 | Składnik sylibininowy do leczenia zapalenia wątroby |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08849759T PL2219642T3 (pl) | 2007-11-15 | 2008-11-14 | Komponent sylibininy do leczenia zapalenia wątroby |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20110182858A1 (pl) |
| EP (2) | EP2392326B9 (pl) |
| JP (1) | JP5349486B2 (pl) |
| KR (1) | KR101435242B1 (pl) |
| CN (1) | CN102300570B (pl) |
| AT (1) | ATE525070T1 (pl) |
| AU (1) | AU2008323156B2 (pl) |
| CA (1) | CA2703834C (pl) |
| DK (1) | DK2219642T3 (pl) |
| ES (2) | ES2374117T3 (pl) |
| MX (1) | MX2010005107A (pl) |
| PL (2) | PL2219642T3 (pl) |
| PT (1) | PT2219642E (pl) |
| WO (1) | WO2009062737A1 (pl) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5841048B2 (ja) * | 2009-05-14 | 2016-01-06 | エウロメッド・エセ・ア | ウイルス性肝炎の治療のための非晶質シリビニン |
| WO2011051742A1 (en) * | 2009-10-28 | 2011-05-05 | Modutech S.A. | Preparation comprising amino acids and plants and its activity in the alcohol detoxification |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2583677A3 (en) | 2011-10-21 | 2013-07-03 | Abbvie Inc. | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon. |
| DE202012012955U1 (de) | 2011-10-21 | 2014-07-14 | Abbvie Inc. | Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV |
| WO2015112171A1 (en) * | 2014-01-27 | 2015-07-30 | Kaohsiung Medical University | A silibinin nanoparticle and a method of treating hepatitis c thereof |
| AU2015222678B2 (en) * | 2014-02-26 | 2018-11-22 | Commonwealth Scientific And Industrial Research Organisation | Process of forming a photoactive layer of a perovskite photoactive device |
| ES2905458T3 (es) * | 2014-10-09 | 2022-04-08 | Distretto Tecnologico Sicilia Micro E Nano Sistemi S C A R L | Formulaciones nanoestructuradas para la administración de silibinina y otros principios activos para el tratamiento de enfermedades oculares |
| CN109715250A (zh) * | 2015-10-02 | 2019-05-03 | 科罗拉多州立大学董事会法人团体 | 局部用水飞蓟宾制剂及其用途 |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| JP6765273B2 (ja) * | 2016-10-05 | 2020-10-07 | 株式会社ファンケル | シリマリン粉砕物 |
| CN111841501A (zh) * | 2020-06-23 | 2020-10-30 | 五邑大学 | 一种治疗炎症性疾病的药物组合物及其应用 |
| KR20230019398A (ko) * | 2021-07-30 | 2023-02-08 | 경희대학교 산학협력단 | 항바이러스 조성물 및 이의 이용 |
| CN117269374B (zh) * | 2023-11-22 | 2024-01-16 | 汤臣倍健股份有限公司 | 一种水飞蓟提取物中人为掺假的鉴别方法 |
| CN117919256B (zh) * | 2024-03-25 | 2024-05-24 | 潍坊众邦制药有限公司 | 一种含有药用甾醇活性物质组合物在制备治疗肝炎的用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061765A (en) * | 1973-01-19 | 1977-12-06 | Dr. Madaus & Co. | Polyhydroxyphenylchromanone salts and therapeutic composition |
| DE3442639A1 (de) * | 1984-11-22 | 1986-05-22 | Dr. Madaus & Co, 5000 Köln | Flavolignanderivate, verfahren zu deren herstellung und arzneimittel, die diese verbindungen enthalten |
| DE3537656A1 (de) | 1984-11-22 | 1986-05-22 | Dr. Madaus GmbH & Co, 5000 Köln | Verfahren zur herstellung von isosilybinfreiem silibinin und arzneimittel, enthaltend silibinin |
| IT1215291B (it) | 1985-07-17 | 1990-01-31 | Inverni Della Beffa Spa | Complessi di flavanolignani con fosfolipidi, loro preparazione e relative composizioni farmaceutiche. |
| IT1241673B (it) | 1989-10-09 | 1994-01-27 | Istituto Biochimico Italiano | Complessi di inclusione di silibinina con ciclodestrina, loro preparazione e composizioni farmaceutiche che li contengono. |
| DE4401902C2 (de) * | 1994-01-24 | 2000-02-03 | Madaus Ag | Verwendung von Flavolignanen als Adjuvans in der Tumortherapie |
| JP2002504514A (ja) * | 1998-02-27 | 2002-02-12 | ニュートラマックス ラボラトリーズ，インコーポレイテッド | 肝臓傷害の予防、治療及び修復のためのｌ−エルゴチオネイン、ノゲシ及びｓ−アデノシルメテオニン |
| WO1999055326A1 (en) * | 1998-04-30 | 1999-11-04 | Vit-Immune, L.C. | Method of treatment of glutathione deficient mammals |
| EP1133287A2 (en) * | 1998-11-24 | 2001-09-19 | Hollis-Eden Pharmaceuticals Inc. | Use of 17-ketosteroids for the treatment of hepatitis c virus and other togaviruses |
| US6849254B1 (en) * | 1999-04-19 | 2005-02-01 | Schering Corporation | HCV combination therapy |
| WO2002067853A2 (en) * | 2000-10-06 | 2002-09-06 | Probiochem, Llc | A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine |
| US6699900B2 (en) | 2001-04-07 | 2004-03-02 | Jan E. Zielinski | Hydrophilic and lipophilic silibinin pro-forms |
| CN100451501C (zh) | 2003-08-26 | 2009-01-14 | 株式会社东芝 | 冰箱 |
| US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
| CN1762345A (zh) | 2005-09-29 | 2006-04-26 | 丛晓东 | 一种水飞蓟宾注射剂及其制备方法 |
| CN100389767C (zh) * | 2005-09-30 | 2008-05-28 | 天津药物研究院 | 一种含活性成分水飞蓟宾及其盐经注射给药的稳定的药物组合物 |
| CN100534992C (zh) * | 2005-12-26 | 2009-09-02 | 浙江海正药业股份有限公司 | 水飞蓟宾酯类衍生物及其制备方法和制备药物的用途 |
| CN101244059B (zh) | 2008-03-31 | 2010-11-17 | 广州佳科生物科技有限公司 | 一种复方水飞蓟宾注射剂及其制备方法和应用 |
| CN101439018A (zh) | 2008-11-11 | 2009-05-27 | 扬子江药业集团四川海蓉药业有限公司 | 一种静脉注射用水飞蓟宾类化合物乳剂及其制备方法 |
-
2008
- 2008-11-14 ES ES08849759T patent/ES2374117T3/es active Active
- 2008-11-14 AT AT08849759T patent/ATE525070T1/de active
- 2008-11-14 AU AU2008323156A patent/AU2008323156B2/en not_active Ceased
- 2008-11-14 CN CN200880116206.3A patent/CN102300570B/zh not_active Expired - Fee Related
- 2008-11-14 EP EP11005445.9A patent/EP2392326B9/en not_active Not-in-force
- 2008-11-14 JP JP2010533503A patent/JP5349486B2/ja not_active Expired - Fee Related
- 2008-11-14 US US12/742,916 patent/US20110182858A1/en not_active Abandoned
- 2008-11-14 KR KR1020107011714A patent/KR101435242B1/ko not_active Expired - Fee Related
- 2008-11-14 PT PT08849759T patent/PT2219642E/pt unknown
- 2008-11-14 CA CA2703834A patent/CA2703834C/en not_active Expired - Fee Related
- 2008-11-14 PL PL08849759T patent/PL2219642T3/pl unknown
- 2008-11-14 MX MX2010005107A patent/MX2010005107A/es active IP Right Grant
- 2008-11-14 WO PCT/EP2008/009659 patent/WO2009062737A1/en not_active Ceased
- 2008-11-14 PL PL11005445T patent/PL2392326T3/pl unknown
- 2008-11-14 ES ES11005445.9T patent/ES2662700T3/es active Active
- 2008-11-14 EP EP08849759A patent/EP2219642B1/en not_active Not-in-force
- 2008-11-14 DK DK08849759.9T patent/DK2219642T3/da active
-
2013
- 2013-04-26 US US13/871,045 patent/US9248115B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100094981A (ko) | 2010-08-27 |
| JP2011503133A (ja) | 2011-01-27 |
| ES2374117T3 (es) | 2012-02-13 |
| ATE525070T1 (de) | 2011-10-15 |
| CA2703834A1 (en) | 2009-05-22 |
| US20130236420A1 (en) | 2013-09-12 |
| HK1142270A1 (en) | 2010-12-03 |
| AU2008323156B2 (en) | 2012-05-31 |
| EP2219642B1 (en) | 2011-09-21 |
| KR101435242B1 (ko) | 2014-08-29 |
| ES2662700T9 (es) | 2018-08-27 |
| EP2392326B9 (en) | 2018-09-05 |
| EP2392326B1 (en) | 2018-01-24 |
| EP2392326A1 (en) | 2011-12-07 |
| US9248115B2 (en) | 2016-02-02 |
| JP5349486B2 (ja) | 2013-11-20 |
| CN102300570A (zh) | 2011-12-28 |
| AU2008323156A1 (en) | 2009-05-22 |
| PL2219642T3 (pl) | 2012-02-29 |
| US20110182858A1 (en) | 2011-07-28 |
| CA2703834C (en) | 2014-05-20 |
| WO2009062737A1 (en) | 2009-05-22 |
| ES2662700T3 (es) | 2018-04-09 |
| DK2219642T3 (da) | 2011-12-05 |
| EP2219642A1 (en) | 2010-08-25 |
| MX2010005107A (es) | 2010-05-27 |
| PT2219642E (pt) | 2011-10-18 |
| CN102300570B (zh) | 2015-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2392326T3 (pl) | Składnik sylibininowy do leczenia zapalenia wątroby | |
| GB0700436D0 (en) | Impulse therapy for enhanced blood circulation in the body | |
| IL180565A0 (en) | An improved stopcock for administering medicaments into the patient's body | |
| PL2125004T3 (pl) | Synergiczne zastosowanie terapeutyczne koncentratów czynników zespołu protrombiny z koncentratami FVIII | |
| IL186662A (en) | Use of bis (thiohydrazide amide) to prepare a drug for the treatment of human cancer | |
| MY204500A (en) | Dosing regimen associated with long acting injectable paliperidone esters | |
| PL2254869T3 (pl) | Nowe pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób bazujących na ekspresji CX3CR1 i p40 | |
| IL196745A (en) | Idabanon for use in providing mucosal pathways to treat disease | |
| SI2061513T1 (sl) | Postopek zdravljenja pacientov s hepatitisom c | |
| PL2083837T3 (pl) | Terapeutyczne zastosowanie co najmniej jednej neurotoksyny botulinowej do leczenia bólu wywołanego co najmniej jednym środkiem przeciwnowotworowym | |
| TWI372056B (en) | Novel medicament combinations for the treatment of respiratory diseases | |
| IL211810A0 (en) | Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis | |
| MX2009001433A (es) | Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica. | |
| IL186780A0 (en) | Combination therapy in the treatment of cancer | |
| PT1670489E (pt) | Utilização de xénon com hipotermia para o tratamento de asfixia neonatal | |
| ZA200806949B (en) | Medicinal formulation for the treatment for hepatitis C | |
| MY146657A (en) | Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas | |
| IL177609A (en) | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma | |
| GB0512593D0 (en) | Treatment device for the human body | |
| GB0415181D0 (en) | Compounds for use in the treatment of infection | |
| GB0710277D0 (en) | Use of antivirals in the treatment of medical disorders | |
| WO2008003514A3 (en) | Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy | |
| PL1714647T3 (pl) | Zastosowanie agomelatyny do wytwarzania leku do leczenia zaburzeń dwubiegunowych | |
| TW200740455A (en) | PEG-IFN alpha and ribavirin for HBV treatment | |
| GB0509911D0 (en) | Medical treatment aid for use in treating children |